Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report
Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple...
Main Authors: | Steven R. Schuster, Barbara A. Pockaj, Mary R. Bothe, Paru S. David, Donald W. Northfelt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2012-09-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2075-4426/2/3/71 |
Similar Items
-
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01) -
Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01) -
Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis
by: Ping Zhou, et al.
Published: (2020-12-01) -
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01) -
How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)